title: Prognostic relevance and therapeutic implications of centromere protein F expression in patients with esophageal squamous cell carcinoma.
abstract: Centromere protein F (CENP-F), a cell cycle-regulated centromere protein, has been shown to affect numerous tumorigenic processes. This study aimed to clarify the prognostic significance of CENP-F expression in patients with esophageal squamous cell carcinoma (ESCC). The levels of CENP-F messenger RNA and protein were higher in ESCC cell lines than in the normal tissues. An immunohistochemical analysis of paired tissue specimens showed that the CENP-F expression was higher in tumorous tissues than in the adjacent non-tumorous tissues (P < 0.001). Moreover, there was a significant correlation between CENP-F expression and gender (P = 0.012), clinical stage (P = 0.039), and T classification (P = 0.026). Patients with higher CENP-F expression had shorter overall survival than those with lower CENP-F expression (P = 0.009). Multivariate Cox analysis indicated that CENP-F expression is an independent prognostic factor for overall survival (hazard ratio = 0.582, 95% confidence interval = 0.397-0.804, P = 0.041). Importantly, it was found that zoledronic acid (ZOL) could significantly enhance the chemotherapeutic sensitivity of ESCC cell lines with high CENP-F expression to cisplatin, although ZOL alone only exhibited a minor inhibitory effect to ESCC cells. In summary, these findings demonstrate that CENP-F may serve as a valuable molecular marker for predicting the prognosis of ESCC patients. In addition, the data indicate a potential benefit of combining ZOL with cisplatin in ESCC, suggesting that CENP-F expression may have therapeutic implications.
authors.affiliation: Department of Medical Oncology, The 174th Hospital of Chinese P.L.A, The Affiliated Chenggong Hospital of Xiamen University, Xiamen, China.
authors.forename: Y-J
authors.initials: YJ
authors.lastname: Mi
authors.forename: J
authors.initials: J
authors.lastname: Gao
authors.forename: J-D
authors.initials: JD
authors.lastname: Xie
authors.forename: J-Y
authors.initials: JY
authors.lastname: Cao
authors.forename: S-X
authors.initials: SX
authors.lastname: Cui
authors.forename: H-J
authors.initials: HJ
authors.lastname: Gao
authors.forename: S-P
authors.initials: SP
authors.lastname: Yao
authors.forename: T
authors.initials: T
authors.lastname: Liu
authors.forename: Y-Y
authors.initials: YY
authors.lastname: Zhang
authors.forename: C-H
authors.initials: CH
authors.lastname: Guo
authors.forename: G-Q
authors.initials: GQ
authors.lastname: Qiu
authors.forename: Y-Q
authors.initials: YQ
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000032:analysis; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D018929:Cell Culture Techniques; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D002868:Chromosomal Proteins, Non-Histone / Q000032:analysis* / Q000235:genetics; D002945:Cisplatin / Q000494:pharmacology; D004164:Diphosphonates / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D004938:Esophageal Neoplasms / Q000473:pathology*; D004947:Esophagus / Q000473:pathology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D008297:Male; D008840:Microfilament Proteins / Q000032:analysis* / Q000235:genetics; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D012737:Sex Factors; D015996:Survival Rate; D000077211:Zoledronic Acid
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D002868:Chromosomal Proteins, Non-Histone; D004164:Diphosphonates; D007093:Imidazoles; D008840:Microfilament Proteins; C094772:centromere protein F; D000077211:Zoledronic Acid; D002945:Cisplatin